CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-54582

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-54582-100ug
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Protein Array

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # LPFS2/1611

Format

Azide and BSA Free

Concentration

1 mg/ml

View all CD27/TNFRSF7 Antibodies »

Product Specifications

Immunogen

Recombinant full-length human CD27/TNFRSF7 protein (Uniprot: P26842)

Localization

Cell Surface

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Theoretical MW

120 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Description

1.0 mg/ml of antibody purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS WITHOUT BSA & azide. Also available at 200 ug/ml WITH BSA & azide (NBP2-53196).

Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.

Scientific Data Images for CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Immunocytochemistry/ Immunofluorescence: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Immunocytochemistry/Immunofluorescence: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582] - Immunofluorescence staining of Ramos cells using CD27/TNFRSF7 Antibody (LPFS2/1611) followed by goat anti-Mouse IgG conjugated to CF488 (green). Nuclei are stained with Red Dot.
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582] - Formalin-fixed, paraffin-embedded human Tonsil stained with CD27/TNFRSF7 Antibody (LPFS2/1611).
Flow Cytometry: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Flow Cytometry: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582]

Flow Cytometry: CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free [NBP2-54582] - Flow Cytometric Analysis of Ramos cells using CD27/TNFRSF7 Mouse Monoclonal Antibody (LPFS2/1611) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
View 3 more images

Applications for CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

0.5 - 1 ug/million cells

Immunocytochemistry/ Immunofluorescence

0.5 - 1 ug/ml

Immunohistochemistry-Paraffin

0.5 - 1.0 ug/ml
Application Notes
ELISA: For coating, order antibody without BSA).
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris buffer with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
Optimal dilution for a specific application should be determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

10 mM PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20 to -80C. Avoid freeze-thaw cycles.

Background: CD27/TNFRSF7

CD27, also referred to as tumor necrosis factor receptor superfamily, member 7 (TNFRSF7), is a type I transmembrane glycoprotein that functions as a co-stimulatory T cell receptor and is expressed on the surface of T cells, natural killer (NK) cells, and B cells (1,2). The human CD27 protein is 260 amino acids (aa) in length and consists of a 19 aa signal sequence, 172 aa extracellular domain (ECD) containing three characteristic cysteine-rich domains (CRDs), a 21 aa helical transmembrane region, and a 48 aa cytoplasmic tail domain (3,4). The CD27 protein has a theoretical molecular weight (MW) of 29 kDa, but is typically is closer to 50-55 kDa due to N-linked and O-linked glycosylation (3). Mouse CD27 cDNA encodes a 250 aa protein with a theoretical molecular weight of 28 kDa (5). Human CD27 shares ~64% aa sequence identity with mouse CD27 protein.

Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).

References

1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629

2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001

3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025

4. Uniprot (P26842)

5. Uniprot (P41272)

6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32

7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y

Alternate Names

CD27, TNFRSF7

Gene Symbol

CD27

Additional CD27/TNFRSF7 Products

Product Documents for CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD27/TNFRSF7 Antibody (LPFS2/1611) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.